Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Expenses (2016 - 2025)

Neurocrine Biosciences' Operating Expenses history spans 16 years, with the latest figure at $594.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 22.42% year-over-year to $594.6 million; the TTM value through Dec 2025 reached $2.2 billion, up 25.58%, while the annual FY2025 figure was $2.2 billion, 25.58% up from the prior year.
  • Operating Expenses reached $594.6 million in Q4 2025 per NBIX's latest filing, up from $555.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $594.6 million in Q4 2025 to a low of $205.1 million in Q1 2021.
  • Average Operating Expenses over 5 years is $396.7 million, with a median of $372.0 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 97.79% in 2021, then dropped 22.18% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $348.3 million in 2021, then dropped by 11.4% to $308.6 million in 2022, then grew by 18.24% to $364.9 million in 2023, then soared by 33.1% to $485.7 million in 2024, then increased by 22.42% to $594.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Operating Expenses are $594.6 million (Q4 2025), $555.9 million (Q3 2025), and $541.9 million (Q2 2025).